Goldman Sachs Group Inc (GS)’s Tesla Motors Inc (TSLA) Price Target at $84

The stock of Tesla Motors Inc (NASDAQ:TSLA) has been performing very well, surging by almost 50% since the beginning of the year. However, over the past month, the stock is down by over 3%, falling from the $240 mark to around $223 it is trading at the moment. However, taking into account the analysts’ ratings and remarks on the stock, Tesla is still performing great. It is notable here to point out that last year, in July, Goldman Sachs Group Inc (NYSE:GS) has announced an $84 target price for Tesla Motors Inc (NASDAQ:TSLA)’s stock, which was over 30% below the actual stock price of the company at that moment. On the back of the news the stock dropped by more than 10%, which was one of its highest downfalls.

Tesla Motors Inc (NASDAQ:TSLA)

Despite a pessimistic prognosis from Goldman Sachs Group Inc (NYSE:GS), the stock of Tesla Motors Inc (NASDAQ:TSLA) managed to recover and has gained more than 70% from July, 2013. The company has reported a great performance with 22,000 Model S sold last year, and during 2014, the company has already launched the sale of its Model S sedan in the UK, and China which is in line with its expansion path. The company plans to deliver 35,000 vehicles during this year, according to its 10-Q report, which will represent a more than 50% increase on the year.

In this way, Tesla Motors Inc (NASDAQ:TSLA)’s financial performance, as well as the activity of its stock, has beaten the estimates of the Goldman Sachs analysts so far. Earlier this year, Goldman Sachs Group Inc (NYSE:GS) has set a $200 price target for Tesla Motors Inc (NASDAQ:TSLA), with a “Neutral” rating, which however, is still below the current situation.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!